EGFR and non-small cell lung carcinoma: They identified the EGFR activating mutation in CTCs in 92% of metastatic patients with NSCLC and detected the drug-resistant mutation T790M in CTCs of 33% of patients who responded to tyrosine kinase inhibitor therapy and in 64% of patients who exhibited clinical progression67.